A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
Completed · Phase 3 · NCT05566639
Conditions: Seasonal Influenza
At a glance
- Research payments reported, 2025
- $33,087
- U.S. investigators named
- 5
- Sites paid
- 6
- Planned or actual enrollment
- 22,502
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1010 (biological), Fluarix Quadrivalent (biological)
- Dates
- Started 2022-09-14; completion 2024-01-05
- Results posted
- Yes
The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.
From ClinicalTrials.gov, last updated 2025-01-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $33,087 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Dena E. Petersen, MD Family Medicine · Tucson, AZ
- Manuchehr M. Darani, M.D. Gastroenterology · Santa Ana, CA
- Daniel Johnson, D.O. Family Medicine · San Diego, CA
- Mark J. Rosenthal, D.O. Family Medicine · Homestead, FL
- Vicki E. Miller, M.D. Family Medicine · Pasadena, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Marvel Clinical Research 002 LLC $14,981
- Clinical Site PArtners Inc $8,000
- Noble Clinical Research LLC $4,894
- Alliance for Multispecialty Research LLC $3,322
- Artemis Headlands LLC $1,600
- Dynamed Clinical Research LP $290
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.